Li H, Liang X, Qin S, Chen X, et al. First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis. PLoS One 2025;20:e0324057.
PMID: 40378108